Anastrozole Tablet
Product Images NDC 42291-016

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 42291-016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

90 (016 90)

This appears to be a mix of random text that does not form a coherent description. It is likely a printout of a label or packaging for a medication. Therefore, a useful description cannot be generated.*

FDA Label Image

30 (016.30)

This is a description of a prescription medication called Nastrozole. It comes in the form of tablets with a total of 30 tablets in a package. The medication is available only with a prescription. There are also some unreadable characters at the beginning of the text that cannot be used to provide additional details.*

FDA Label Image

Chemical Structure (Anastrozole 01)

FDA Label Image

Figure 1 (Anastrozole 02)

This is a tabular data of disease-free survivals in months for patients undergoing treatment with randomized anastrozole or tamoxifen. There are 2 columns that represent treatments, i.e., "anastrozole" and "tamoxifen". The rows show the proportion of patients alive and disease-free for certain time points. Each row displays the number of months since the treatment began, and the number of patients available at each time-point.*

FDA Label Image

Figure 2 (Anastrozole 03)

FDA Label Image

Figure 3 (Anastrozole 04)

This is a Kaplan-Meier survival plot for patients under randomized treatment of Anastrozole versus Tamoxifen. The plot shows the proportion of event-free patients over time measured in months. The Y-axis has been truncated for clarity. The number of patients at risk is shown below the plot.*

FDA Label Image

Figure 4 (Anastrozole 05)

This appears to be a graph of Kaplan-Meier curves, which are used to estimate survival or event-free probabilities over time. The graph compares two randomized treatments of anastrozole and tamoxifen over a period of 120 months or 10 years. The x-axis shows time to event in months, and the y-axis shows the proportion of patients who remain event-free over time. The legend indicates the number of patients at risk for each treatment group. However, without further context, it is not possible to determine what event or disease is being studied.*

FDA Label Image

Figure 5 (Anastrozole 06)

This appears to be a graph or chart showing the time to progression (in months) for randomized treatment of anastrozole and tamoxifen. It is not clear what the progression is referring to, but the chart shows the proportion not progressing over time, with data points at various months. The graph shows a gradual decrease in the proportion not progressing over time.*

FDA Label Image

Figure 6 (Anastrozole 07)

This is a graph or chart showing the progression of a treatment using anastrozole and tamoxifen over a period of 40 months. The horizontal axis shows the time in months while the vertical axis shows the number of patients at risk. The title suggests that the proportion did not progress, but without additional context or a legend, it is not clear what the proportion refers to.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.